<DOC>
	<DOCNO>NCT03052933</DOCNO>
	<brief_summary>COPGEM ( Copanlisib Gemcitabine ) chemotherapy regimen propose salvage treatment relapse refractory peripheral T-cell NK/T-cell lymphoma study protocol , would expect feasible effective group patient . Copanlisib ( BAY 80-6946 ) , highly selective potent class-1 PI3K inhibitor sub-nanomolar IC50s PI3Kα PI3Kδ , demonstrate activity relapsed/refractory , aggressive NHLs , suggest ORR 50 % T-cell lymphoma . Gemcitabine demonstrate clinical antitumor activity PTCLs include NK/T-cell lymphomas single-agent ( ORR 30-50 % ) combination therapy , limited extramedullary toxicity . Considering evidence activity agent PTCLs , investigator propose target therapy copanlisib combination gemcitabine exhibit early elimination rapidly grow tumor cell rational therapeutic modality use relapse refractory PTCLs , overlap toxicity manage .</brief_summary>
	<brief_title>Copanlisib Gemcitabine Relapsed/Refractory PTCL</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histologically confirm relapsed refractory PTCL NK/Tcell lymphoma , exclude primary cutaneous Tcell lymphoma , Sezary syndrome base WHO classification , Age ≥ 19 ECOG performance status ≤ 2 least one bidimensional measurable lesion Laboratory value Serum Cr &lt; 1.5 mg/dL CrCl &gt; 50 mL/min Transaminase ( AST/ALT ) &lt; 2.5 x ULN ( &lt; 5 x ULN presence lymphoma involvement liver ) Bilirubin &lt; 1.5 x UNL ( &lt; 3 x ULN presence lymphoma involvement liver Gilbert syndrome ) PT ( INR ) ≤ 1.5 x ULN aPTT ≤ 1.5 x ULN Lipase ≤ 1.5 x ULN Hematologic function : absolute neutrophil count ( ANC ) ≥ 1,500/µL platelet count ≥ 75,000/µL , hemoglobin ≥ 8 g/dL Left ventricular ejection fraction ( LVEF ) ≥ low limit normal institution Women childbearing potential men must agree use adequate contraception sexually active Written inform consent Bcell NHL , primary cutaneous Tcell lymphoma Sezary syndrome Patients previous history lymphoma involvement CNS . History previous gemcitabine therapy Type I II diabetes mellitus HbA1c &gt; 8.5 % screen History chronic hepatitis B ; subject positive HBsAg exclude study . However , subject HBcAb eligible negative HBV DNA quantification History chronic hepatitis C ; subject positive HCV IgG eligible negative HCVRNA quantification Known history human immunodeficiency virus ( HIV ) infection History concurrent condition interstitial lung disease severity and/or severely impaired lung function Any malignancy within past 3 year except curatively treat basal cell carcinoma skin , carcinoma situ uterine cervix , papillary carcinoma thyroid Other serious illness medical condition Congestive heart failure &gt; NYHA class 2 ( Appendix III ) Unstable angina newonset angina within last 3 month ; Myocardial infarction within 6 month prior study entry History significant neurological psychiatric disorder include dementia seizure Uncontrolled hypertension despite optimal medical management ( per investigator 's opinion ) Arterial venous thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism within 6 month start study treatment Nonhealing wound , ulcer , bone fracture Active uncontrolled infection ( viral , bacterial , fungal infection ) Patients evidence history bleed diathesis . Any hemorrhage bleeding event ≥ grade 3 within 4 week start study medication Proteinuria estimate urine protein/creatinine ratio &gt; 3.5 random urine sample Concurrent diagnosis pheochromocytoma Other previous concurrent treatment Ongoing immunosuppressive therapy Radiotherapy immune/chemotherapy le 4 week start treatment Radioimmunotherapy autologous transplant le 3 month start treatment Myeloid growth factor within 14 day prior treatment start Blood platelet transfusion within 7 day prior treatment start Systemic continuous corticosteroid therapy daily dose high 15 mg prednisone equivalent History receive allogeneic bone marrow organ transplant Major surgical procedure significant trauma injury within 28 day start study medication , open biopsy within 7 day start study treatment Antiarrhythmic therapy ( betablockers digoxin permit ) Use CYP3A4 inhibitor inducer Pregnant lactate woman , woman childbearing potential employ adequate contraception Concomitant administration experimental drug investigation</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>copanlisib</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>peripheral T-cell lymphoma</keyword>
	<keyword>extranodal NK/T-cell lymphoma</keyword>
</DOC>